A bipartisan bill introduced in Congress on October 29, 2026, would stop a planned change to the way safety-net hospitals and clinics buy discounted medicines, and would bar pharmacy benefit managers and insurers from practices that sponsors say drain resources away from patient care. The Preserving Rules Ordered for The Entities Covered Through (PROTECT) 340B Act of 2026, introduced by Representative Doris Matsui, a Democrat from California, and Representative Tracey Mann, a Republican from Kansas, targets the federal 340B Drug Pricing Program, a decades-old system that allows eligible providers to purchase outpatient drugs at reduced prices.
The bill’s most urgent provision, according to its sponsors, is to terminate the 340B Rebate Model Pilot Program before its planned implementation on January 1, 2027. Under the current system, eligible providers buy drugs at an upfront discount. Under a rebate model, providers would instead pay a higher price first and seek a rebate afterwards, a shift that sponsors argue would create cash-flow problems, administrative delays and disputes over individual prescriptions. The bill would require the Department of Health and Human Services to end the pilot and would prohibit the establishment of a similar programme.
The measure is bipartisan in its leadership and in its original cosponsors, who include both Democrats and Republicans from urban and rural districts. That breadth matters because the 340B programme itself touches very different kinds of providers: large safety-net hospitals in cities, community health centres serving low-income patients, rural hospitals with thin margins, and clinics specialising in HIV care and other chronic conditions. Sponsors argue that, despite those differences, the providers share a common interest in keeping discounts predictable and available upfront.
Introduction, however, is not enactment. The bill must still pass the House and the Senate and be signed by the president before any of its protections take effect. Its sponsors are therefore racing a calendar as much as a policy debate: if Congress does not act before the pilot’s planned start date, providers could face a new payment system that the bill’s supporters say they are ill-equipped to absorb.
How the PROTECT 340B Act Would Protect Drug Discounts
The 340B programme was enacted by Congress in 1992 with bipartisan support and is overseen by the Health Resources and Services Administration, part of the Department of Health and Human Services. In exchange for having their drugs covered by Medicaid, pharmaceutical manufacturers are required to offer discounts to eligible safety-net and rural providers. Those providers, in turn, are expected to use the savings to stretch limited resources and serve patients in underserved communities.
According to the sponsors’ release, the programme allowed safety-net hospitals, local health centres and other eligible entities to purchase 100 billion dollars in discounted outpatient medications last year. That figure illustrates the scale of the programme: it is not a marginal subsidy, but a central part of how many safety-net providers finance care, including free screenings, emergency financial assistance for families, community health education and other services that are not fully reimbursed elsewhere.
The PROTECT 340B Act would defend that model in several ways. First, it would end the rebate pilot and block a similar replacement, preserving upfront discounts as the default. Second, it would prohibit discriminatory practices by pharmacy benefit managers, the middlemen who manage prescription drug benefits for insurers and employers, and by health insurers themselves. Third, it would create an independent, centralised process for identifying and resolving duplicate discounts, a long-running source of disputes in the programme.
The bill’s protections would extend to Medicare Part D and Medicare Advantage, two large programmes through which many older and disabled patients receive drug coverage. Sponsors say that extension is necessary because discriminatory reimbursement or network restrictions in those programmes can have the same effect as in commercial insurance: reducing the value of the 340B discount even though the provider remains eligible for it.
Upfront Discounts Versus Delayed Rebates
The core policy dispute is deceptively simple: should a safety-net provider pay less at the counter, or pay full price and wait for money back? Sponsors and provider groups argue that the difference is decisive for organisations operating on tight margins. An upfront discount is certain, immediate and usable for planning. A rebate, they say, introduces delay, uncertainty and administrative work, as each prescription can become subject to verification, dispute and protracted payment.
Provider groups cited by the sponsors warn that the consequences would fall on patients. According to a 2025 survey by 340B Health cited in the sponsors’ release, 92 percent of responding hospitals said they would have to reduce free or discontinued medications if manufacturers broadly implemented rebate models. That survey result is presented by supporters as evidence of the risk, although it reflects hospitals’ own assessments of their finances rather than an independent forecast of what a pilot would actually do in practice.
Supporters of a rebate approach, including some in the pharmaceutical industry, argue from a different premise. They contend that the current system can produce duplicate discounts, in which a manufacturer gives both a 340B discount and a Medicaid rebate on the same drug, and that a rebate model with better tracking could improve programme integrity. The PROTECT 340B Act’s sponsors dispute that a wholesale shift to rebates is the right remedy, pointing instead to their proposed independent clearinghouse as a way to resolve duplicate-discount questions without abandoning upfront pricing.
The clearinghouse proposal is therefore central to the bill’s compromise logic. It would establish a third-party process to identify and resolve duplicate discounts while protecting confidential claims data and allowing providers to submit information retrospectively. If it worked as intended, supporters say, it would address a legitimate integrity concern without forcing providers to finance the gap between purchase and rebate. Whether such a system could be built quickly enough, and whether manufacturers and providers would trust its rulings, are questions that committee review would need to examine.
Pharmacy Benefit Managers and the New Enforcement Rules
The second major part of the bill concerns pharmacy benefit managers, often called PBMs, and insurers. Under the bill, those entities could not impose lower reimbursement rates, unfair fees, restrictive pharmacy network requirements or other discriminatory conditions solely because a provider or pharmacy participates in 340B. Sponsors describe those practices as exploiting the programme: the discount is intended for the safety-net provider and its patients, not to be captured by a middleman through a lower payment.
To give that prohibition force, the bill would authorise civil monetary penalties of up to 5,000 dollars per violation per day for PBMs that violate the law. That penalty structure is designed to make non-compliance costly, rather than a routine cost of doing business. It would also create a clearer enforcement path than relying solely on private disputes between providers and PBMs, which can be expensive and slow for smaller clinics and hospitals.
Provider and hospital groups have welcomed the PBM provisions. The California Hospital Association, the National Association of Community Health Centers, the American Society of Health-System Pharmacists and other endorsers listed by the sponsors argue that 340B savings support a wide range of community services, from free health screenings for low-income and unhoused people to support for children and families in financial crisis. Their argument is that every dollar diverted through discriminatory reimbursement is a dollar not spent on those services.
PBMs and insurers, for their part, have generally argued in past 340B debates that their network and reimbursement policies are designed to control costs, ensure quality and prevent programme abuse, and that restrictions on their practices could raise costs elsewhere in the system. Those broader industry arguments were not detailed in the sponsors’ release for this bill, and any specific claim about a particular PBM’s practices would need to be tested against evidence in individual cases. The bill itself, however, would settle the legal question in favour of providers by making 340B participation an impermissible basis for discriminatory treatment.
Support, Opposition and the Road Ahead in Congress
The bill arrives with an unusually broad endorsement list for a health-care measure, including the American Hospital Association, America’s Essential Hospitals, the Children’s Hospital Association, the National Rural Health Association, the Association of American Medical Colleges and the National Association of Counties, among others. Original cosponsors named by the sponsors include Republicans Stephanie Bice of Oklahoma and Dan Meuser of Pennsylvania alongside Democrats including Jim Costa of California, Sharice Davids of Kansas, Debbie Dingell of Michigan and Gwen Moore of Wisconsin.
That coalition reflects the programme’s geography. A rural hospital in Kansas and a community health centre in Sacramento may serve very different populations, but both rely on 340B savings to offset the cost of caring for patients who cannot pay full price. Community health centres alone, according to the National Association of Community Health Centers, serve 52 million people, about one in seven Americans, including one in three people in rural communities. Sponsors argue that a rebate model would hit those centres particularly hard because they lack the cash reserves to wait for rebates.
The bill also builds on earlier bipartisan action. Matsui has previously introduced legislation to protect access through contract pharmacies and led a bipartisan letter signed by 166 members of Congress opposing the administration’s rebate pilot. She also led an effort this year to block federal funding for implementing the rebate model. The new bill consolidates those efforts into a single, freestanding measure that would end the pilot outright rather than merely delaying its funding.
Its path forward is uncertain. Health-care legislation with a January 1 deadline can move quickly if leadership prioritises it, but it can also stall in committee amid competing claims about programme integrity, manufacturer obligations and PBM regulation. As with other measures that must clear both chambers, bipartisan introduction does not guarantee a floor vote, and the bill’s fate will depend on whether its sponsors can keep a cross-party coalition together through committee markup and floor consideration. A reminder of how bipartisan action can still move in the Senate came recently, when the Senate unanimously passed a bipartisan taxpayer assistance bill, leaving its fate to the House (https://usnbreaking.com/senate-unanimously-passes-bipartisan-taxpayer-assistance-bill-leaving-its-fate-to-the-house/).
For patients and providers, the practical question is what happens on January 1 if Congress does not act. Under the pilot as planned, providers would face a new rebate process; under the bill, they would keep upfront discounts and gain new protections against discriminatory PBM practices. That contrast is why sponsors have framed the bill as urgent, and why its progress in the coming weeks will be watched closely by hospitals, clinics and pharmacies across the country. The debate will continue well beyond the week of introduction, but the deadline gives it a concreteness that many health-care bills lack.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from Congresswoman Doris Matsui, Business Wire and BriefGlance.